Principal investigator for TH1902 She is the principal investigator at MD Anderson also in charge of TH1902 trial.
This was her comments about another PDC at the Clininc:
“In this phase I study, CBX-12 demonstrated safety and tolerability, without significant gastrointestinal toxicity. We also saw signal of antitumor activity in multiple tumor types, said principal investigator, Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.”
https://www.globenewswire.com/news-release/2022/10/28/2543911/0/en/Cybrexa-Therapeutics-Presents-Findings-from-First-in-Human-Study-of-CBX-12-as-a-Plenary-Oral-Presentation-at-34th-EORTC-NCI-AACR-Symposium.html
Looking at her profile she seems to be the right choice for TH1902 so hopefully we get a similar PR with encouraging comments from her about TH1902.
“Funda Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics -- the Phase I Program, and the Medical Director of the Institute for Personalized Cancer Therapy at MD Anderson Cancer Center. She has a basic and translational research program that is focused on molecular therapeutics, to delineate the mechanism of action of each agent targeting this pathway and the molecular alterations useful to prospectively identify patients who will benefit most from each agent, and optimal combination therapies with targeted therapies and novel immune-modulators. She is an active clinical trialist focused on Phase I trials, and rationale combinations, biomarker-driven therapy and immune-oncology.”
Funda Meric-Bernstam | MD Anderson Cancer Center